Oncogenic Ras expression is associated with activation of the DNA damage response (DDR) pathway, as evidenced by elevated DNA damage, primarily DNA double-strand breaks (DSBs), and activation of DNA damage checkpoints, which in primary human cells leads to entry into senescence. DDR activation is viewed as a physiological barrier against uncontrolled proliferation in oncogenic Ras-expressing cells, and arises in response to genotoxic stress due to the production of reactive oxygen species that damage DNA and to hyper-replication stress. Although oncogene-induced senescence (OIS) is considered a tumor suppressor mechanism, the accumulation of DNA damage in senescent cells is thought to cause genomic instability, eventually allowing secondary hits in the genome that promote tumorigenesis. To date, the molecular mechanisms behind DNA repair defects during OIS remain poorly understood. Here, we show that oncogenic Ras expression in human primary cells results in the downregulation of BRCA1 and 53BP1, two key factors in DNA DSB repair by homologous recombination and non-homologous end joining, respectively. As a consequence, Ras-induced senescent cells are hindered in their ability to recruit BRCA1 and 53BP1 to DNA damage sites. Whereas BRCA1 is downregulated at transcripts levels, 53BP1 loss is caused by activation of cathepsin L-mediated degradation of 53BP1 protein. Moreover, we discovered a marked downregulation of vitamin D receptor (VDR) during OIS, and a role for the vitamin D/VDR axis regulating the levels of these DNA repair factors during OIS. This study reveals a new functional relationship between the oncogene Ras, the vitamin D/VDR axis and the expression of DNA repair factors, in the context of OIS. The observed deficiencies in DNA repair factors in senescent cells could contribute to the genomic instability that allows senescence bypass and tumorigenesis.
INTRODUCTION
Expression of oncogenic Ras in primary human cells results in a growth arrest known as oncogene-induced senescence (OIS). [1] [2] [3] This is more commonly observed in human pre-neoplasia than in neoplastic lesions, and is considered a tumor suppressor mechanism. [4] [5] [6] There is strong evidence that establishment of OIS is tightly dependent on persistent activation of the DNA damage response (DDR) pathway owing to replication stress [7] [8] [9] [10] [11] and/or increased levels of reactive oxygen species. 12, 13 In fact, cells expressing oncogenic Ras but unable to activate DDR do not enter senescence. 4, 9 Similarly, oncogene expression in non-replicating cells does not trigger DDR. Although these findings stress the importance of DDR activation during OIS, we have limited understanding about the integrity of DNA repair mechanisms in senescent cells.
Recent studies reported that oncogenic Ras inactivates the BRCA1 DNA repair complex by dissociating BRCA1 from chromatin, coinciding with DNA damage accumulation prior to senescence. 14, 15 Importantly, these cells subjected to DNA damage by ionizing radiation (IR) during replication bypass senescence and become transformed more efficiently than not irradiated cells. Thus, oncogenic Ras-induced BRCA1 loss of function was proposed to predispose senescent cells to additional hits in the genome that promote senescence bypass and eventually cellular transformation.
The reduced association of BRCA1 to chromatin could explain at least in part the accumulation of DNA damage during hyperreplication, owing to inefficient DNA repair by homologous recombination (HR). Previous studies have shown that genomic instability in BRCA1-deficient cells is tightly linked to the function of 53BP1. Recruitment of 53BP1 to DNA double-strand breaks (DSBs) facilitates DNA repair by non-homologous end joining (NHEJ) while inhibiting end resection at the break, a prerequisite for HR. [16] [17] [18] Thus, BRCA1 and 53BP1 seem to compete for DNA repair substrate and facilitate either HR or NHEJ, respectively. This competition is important for the maintenance of genome integrity, with loss of either BRCA1 or 53BP1 resulting in genomic instability and cancer susceptibility. 19, 20 In contrast, loss of 53BP1 alleviates HR defects in BRCA1-deficient cells. Whereas loss of BRCA1 function in mice causes embryonic lethality, depletion of 53BP1 in this context rescues lethality. 18 Thus, 53BP1 loss is synthetically viable with the loss of BRCA1. [21] [22] [23] Moreover, reduced 53BP1 expression is observed in triple negative breast cancers (TNBC) and BRCA1-mutated tumors, suggesting that 53BP1 loss contributes to the survival of BRCA1-deficient cells. 16, 24 Whether or not the function of 53BP1 is altered during Ras-induced senescence remains unknown.
Our studies showed a correlation between 53BP1 and BRCA1 levels in a variety of contexts. Human fibroblasts and cancer cells (MCF7) growth arrested by contact inhibition or serum deprivation exhibit reduced BRCA1 and 53BP1 levels. 25 Growth-arrested cells downregulate BRCA1 expression and upregulate the protease cathepsin L (CTSL), which is responsible for 53BP1 protein degradation. In addition, BRCA1 depletion in MCF7 cells results in genomic instability and growth arrest. However, after approximately 2-3 weeks in growth arrest, BRCA1-deficient cells activate CTSL-mediated degradation of 53BP1 as a means to overcome the proliferation arrest induced by BRCA1 loss. 24 Similarly, depletion of lamin A/C proteins results in reduced BRCA1 expression and activation of CTSL-mediated degradation of 53BP1, concomitant with DNA damage accumulation. [26] [27] [28] Altogether, these studies suggest that BRCA1 and 53BP1 levels are downregulated in response to a variety of stress conditions that cause growth arrest. Whether the loss of BRCA1 function during Ras-induced senescence 14 impacts on 53BP1 levels is unknown.
Our analysis of tissue microarrays from breast cancer patients revealed nuclear accumulation of CTSL primarily in TNBC and BRCA1-mutated tumors, 24 and an inverse correlation with 53BP1 levels. These data suggest that nuclear CTSL could contribute to 53BP1 loss. Moreover, subsets of TNBC and most BRCA1-deficient tumors analyzed exhibit reduced vitamin D receptor (VDR) levels, which correlate with the accumulation of nuclear CTSL, and reduced 53BP1 levels. 24 These results suggest that vitamin D/VDR might regulate CTSL-mediated degradation of 53BP1. In support of this notion, vitamin D treatment inhibits CTSL-mediated degradation of 53BP1 in a variety of contexts, including BRCA1deficient and lamin A/C-deficient cells. 24, 26 Overall, these studies suggest a functional relationship between BRCA1, CTSL-mediated degradation of 53BP1 and the vitamin D/VDR axis. Given that Ras-induced senescence causes BRCA1 dissociation from chromatin 14 and that Ras expression upregulates CTSL, [29] [30] [31] [32] we determined whether 53BP1 is downregulated during Ras-induced senescence, and whether vitamin D/VDR regulate this process. Here, we show that the expression of oncogenic Ras (H-Ras G12V ) in primary human fibroblasts results in downregulation of BRCA1 expression and activation of CTSLmediated degradation of 53BP1. In addition, we discover a marked downregulation of VDR during Ras-induced senescence. Importantly, stabilization of VDR via vitamin D treatment restores near normal levels of BRCA1 and 53BP1, and their recruitment to sites of DNA damage. This study demonstrates a functional relationship between the oncogene Ras, the vitamin D/VDR axis and the expression of DNA repair factors, in the context of OIS.
RESULTS
Ras-induced senescence leads to upregulation of CTSL, reduced levels of DNA repair factors and downregulation of VDR Given our findings that CTSL regulates the levels of 53BP1 in tumor and normal cells, [24] [25] [26] we determined whether overexpression of oncogenic Ras results in the activation of this regulatory mechanism in human cells. As previously reported, retroviral transduction of the constitutive active form of H-Ras (H-Ras G12V ) in human primary fibroblasts immortalized with telomerase (BJ+hTert) results in the establishment of senescence, 1-3 as shown by the typical flat morphology, positivity for β-galactosidase (SA-β-Gal) activity ( Figure 1a ), presence of senescence-associated heterochromatic foci (Figure 1b ), accumulation of cells in G2 phase of the cell cycle ( Figure 1c ) and loss of Cyclin A expression ( Figure 1d ). These senescent cells display a marked upregulation of CTSL at protein and transcript levels as assessed by immunoblottting (Figures 1d and e ) and quantitative RT-PCR (qRT-PCR), respectively ( Figure 1f ). Interestingly, CTSL upregulation correlates with a marked decrease in 53BP1 protein (Figures 1d and e ), but not in transcripts levels (Figure 1f ), suggesting that CTSL-mediated degradation of 53BP1 might be activated during OIS.
In addition, oncogenic Ras-induced senescent cells exhibit deficiencies in the DNA repair factors BRCA1 and RAD51, at both protein and transcript levels (Figures 1d-f ). RAD51 decrease might be explained by the fact that this factor is regulated during the cell cycle. 33, 34 In addition, a progressive reduction of RAD51 expression has been reported during replicative senescence. 35 In contrast, there is no evidence for downregulation of BRCA1 or 53BP1 levels during OIS. One study showed, however, that BRCA1 association with chromatin is reduced during Ras-induced senescence, although the global protein levels did not change. 14 In our hands, we find downregulation of BRCA1 at transcript and protein levels in senescent cells expressing H-Ras G12V (Figures 1d-f ). Importantly, the same upregulation of CTSL and downregulation of DNA repair factors BRCA1, RAD51 and 53BP1 were observed in IMR90 cells transduced with oncogenic Ras (Figures 1g-i) , indicating that this is not a cell type-specific phenotype.
Previous studies showed that Ras activation induces VDR mRNA instability in tumor cells and reduces nuclear VDR activity in mouse fibroblasts. 36, 37 Thus, we determined whether VDR levels are altered during OIS. We show that VDR is downregulated at protein and transcripts levels during Ras-induced senescence (Figures 1d-f ).
Overall, these studies reveal a marked reduction in the levels of key factors in DNA repair (53BP1 and BRCA1), and in VDR expression, during Ras-induced senescence. To determine whether these deficiencies are due to growth arrest per se, we used different strategies to induce senescence. BJ+hTert fibroblasts were subjected to bleomycin or hydrogen peroxide treatments and senescence was evaluated by positivity for SA-β-Gal activity (Figure 2a ), decreased Ki67 levels (Figure 2b ), accumulation of cells in G1/G2 phases ( Figure 2c ) and changes in Cyclin A and p21 ( Figure 2d ). Importantly, these strategies to induce senescence do not result in downregulation of BRCA1, 53BP1 or VDR (Figure 2d ), indicating that expression of oncogenic Ras, and not only senescence, is responsible for the deficiencies in these factors during OIS. In addition, we treated human fibroblasts (BJ and IMR90) with hydroxyurea to induce replication stressinduced senescence (Figures 2e-g). We observed downregulation of VDR expression in response to hydroxyurea, but not of DNA repair factors 53BP1 and BRCA1 ( Figure 2g ). These data suggest that VDR deficiency might be linked to replication stress during OIS, but not the DNA repair deficiencies, which are only observed upon expression of oncogenic Ras. In contrast, expression of oncogenic Ras in tumor cell lines (MCF7 and HeLa) did not result in growth arrest or downregulation of VDR or DNA repair factors (Figure 2h ), suggesting that these alterations might involve tumor suppressor mechanisms, which are lost in tumor cells.
CTSL is responsible for 53BP1 loss during Ras-induced senescence During Ras-induced senescence, we found a correlation between upregulation of CTSL expression and reduced 53BP1 protein 
levels, without changes in 53BP1 transcript levels (Figures 1d-g).
To determine whether CTSL is responsible for 53BP1 degradation in this context, we depleted CTSL prior to expression of oncogenic Ras in BJ+hTert cells. Depletion of CTSL prior to Ras expression abrogates 53BP1 loss ( Figure 3a ). Of note, expression of Ras in CTSL-depleted cells results in a slight increase in the levels of the protease, reflecting the dramatic effect that Ras exerts on its expression. In fact, we detected a 53BP1 protein of lower Figure 2 . For caption see page 5366. molecular weight in these cells, possibly indicating that some degradation is taking place. These results demonstrate that CTSL is required for the degradation of 53BP1 during Ras-induced senescence.
Next, we determined whether the decrease in 53BP1 has functional consequences, by assessing the ability of Ras-senescent cells to recruit 53BP1 protein to IR-induced DNA damage sites. Irradiation of control and Ras-senescent cells results in proper activation of the DDR pathway, with 100% of cells being positive for γH2AX IR-induced foci (IRIF) formation (Figures 3b and c) . Interestingly, although the majority of control cells are positive for 53BP1 IRIF formation, Ras-senescent cells exhibit a decreased ability to form 53BP1 IRIF. This is consistent with the reduction in 53BP1 global levels. Importantly, depletion of CTSL rescues the formation of 53BP1 IRIF in Ras-senescent cells. These data indicate that CTSL-mediated degradation of 53BP1 is activated during Rasinduced senescence, hindering the recruitment of this important DNA repair factor to sites of DNA damage.
To determine whether the stabilization of 53BP1 has consequences for OIS, we monitored the entry into senescence of cells depleted of CTSL. As shown in Figure 3d , expression of oncogenic Ras in CTSL-depleted cells results in a more robust G2 arrest, when compared with CTSL-proficient cells expressing Ras, and at all times tested. However, positivity for SA-β-Gal activity was similar in both contexts ( Figure 3e ). These results suggest that although stabilization of 53BP1 promotes a growth arrest in G2, it does not affect the overall extent of OIS.
Downregulation of VDR leads to an imbalance between BRCA1
and 53BP1, which is responsible for premature entry into senescence A functional relationship between BRCA1 and the vitamin D/VDR axis has been previously suggested. Studies showed that vitamin D/VDR regulates indirectly the expression of BRCA1, 38 and that BRCA1 interacts with VDR. 39 Our own studies in normal fibroblasts and fibroblasts derived from patients with Hutchinson Gilford Progeria Syndrome revealed that depletion of VDR results in decreased levels of BRCA1, and accumulation of DNA damage (γH2AX foci) (Kreienkamp et al., unpublished). Given our findings that VDR levels are decreased during Ras-induced senescence, we determined whether VDR deficiency could contribute to DNA repair defects.
As shown in Figure 4a , depletion of VDR in BJ+hTert fibroblasts via lentiviral transduction with two independent shRNAs results in the downregulation of BRCA1 transcripts, concomitant with decreased protein levels ( Figure 4b ), mirroring Ras-induced senescent cells. In contrast, we did not find alterations in CTSL or 53BP1 protein levels upon VDR depletion ( Figure 4b ). Importantly, VDR depletion leads to the accumulation of DNA damage, as shown by increased global levels of γH2AX by immunoblotting ( Figure 4b ), and increased percentage of γH2AXpositive cells by immunofluorescence ( Figure 4c ). Moreover, VDR depletion results in growth arrest and establishment of senescence, as shown by positivity for SA-β-Gal activity (Figure 4d ), accumulation of cells in G1 phase ( Figure 4e ) and high expression of p21 ( Figure 4b ). The effect of VDR depletion triggering senescence was more robust than oncogenic Ras expression. Although growth arrest is established over the course of the first week upon H-Ras G12V transduction, VDR loss-induced growth arrest is established within the third day after VDR depletion.
Consistent with the decrease in BRCA1 levels, VDR-depleted cells were hindered in their ability to form BRCA1 IRIF (Figures 5a  and b ), suggesting that VDR deficiency could contribute to defects in BRCA1-mediated DNA repair by HR during OIS. VDR-depleted cells were able to activate the DDR in response to IR, as shown by positivity for γH2AX IRIF formation (Figures 5c and d) , and did not show deficiencies in 53BP1 IRIF (Figures 5e and f) .
To test directly whether VDR loss affects DNA repair by HR, we depleted VDR in MCF7 cells carrying an HR reporter construct. Depletion of VDR results in a marked decrease in GFP-positive cells, indicating that VDR deficiency hinders DNA repair by HR ( Figure 6a ). Altogether, these data demonstrate that VDR depletion leads to an imbalance between BRCA1 and 53BP1. This scenario is known to induce profound genomic instability and proliferation arrest; phenotypes that are rescued by lowering 53BP1 levels. 24 Thus, one possible explanation for the most robust growth arrest when compared with Ras-expressing cells is that VDR-depleted cells express normal levels of 53BP1, in a context of BRCA1 deficiency. To test this hypothesis, we depleted 53BP1 prior to depletion of VDR in BJ+hTert cells. As shown in Figure 6b , we achieved a marked depletion of both VDR and 53BP1, and BRCA1 levels were maintained in 53BP1-depleted cells, but not in VDRdepleted cells, as expected. Interestingly, depletion of 53BP1 abrogates the ability of BJ+hTert cells to growth arrest upon depletion of VDR, as shown by decreased positivity for SA-β-Gal activity (Figure 6c ), and by proliferation rate (Figure 6d ). These data uncover a critical role for 53BP1 in the establishment of senescence due to VDR loss, as previously shown in the context of BRCA1 depletion. 24 In summary, our results are consistent with VDR transcription factor having a role in the maintenance of genomic stability by being involved in the regulation of BRCA1 expression, and with VDR loss contributing to DNA repair defects during Ras-induced senescence. In contrast, CTSL upregulation and 53BP1 decrease are not observed during VDR loss-induced senescence suggesting that Ras regulates these processes independently of VDR. We also provide evidence for the importance of a balance between 53BP1 and BRCA1 to maintain genome stability and normal proliferation. BJ+hTert fibroblasts were treated with bleomycin or hydrogen peroxide to induce senescence, and with vehicle control, as described in methods. After the treatments, markers of senescence were monitored, including positivity for SA-β-Gal activity (a) and negativity for Ki67 (b), as well as accumulation of cells in G1/G2 phases of the cell cycle (c). Graphs show average ± s.e.m. of five bleomycin treatments and three hydrogen peroxide treatments. (d) Cells treated with bleomycin or hydrogen peroxide that entered senescence were collected and processed for immunoblotting to monitor levels of DNA repair factors and VDR. Note how these treatments did not result in deficiencies in VDR, 53BP1 or BRCA1. Blots are representative of at least three biological repeats. (e) BJ+hTert and IMR90+hTert fibroblasts were treated with HU to induce senescence, and with vehicle control. After the treatment, positivity for SA-β-Gal activity was quantitated. (f) Cell cycle shows accumulation in cells in G1/G2 phases of the cell cycle upon HU treatment. (g) Immunoblots of cells that entered senescence upon HU treatment. Experiments are representative of two biological repeats. (h) Immunoblots of cancer cell lines expressing oncogenic Ras. Note how Ras expression in tumor cells did not alter VDR, 53BP1 or BRCA1 levels.
As expected, vitamin D treatment increases VDR levels, 40 demonstrating that the treatment was effective (Figure 7a ). Interestingly, vitamin D treatment increases BRCA1 protein ( Figure 7a ) and transcripts (Figure 7b ) levels in senescent cells, when compared with vehicle-treated cells. These data support the notion that VDR downregulation contributes to BRCA1 reduction during Ras-induced senescence. In addition, vitamin D stabilizes, at least partially, the levels of 53BP1 protein in senescent cells (Figure 7a ), without affecting 53BP1 transcripts levels (Figure 7b ), which could be explained by the role that vitamin D has inhibiting CTSL activity. 26 These results and data showing that VDR depletion does not activate CTSL-mediated degradation of 53BP1 suggest that VDR deficiency during OIS does not contribute to 53BP1 loss. However, once this mechanism is activated by Ras expression, vitamin D/VDR can inhibit 53BP1 degradation by regulating the levels/activity of CTSL, as previously reported in other contexts. 24, 26 Overall, our results support the notion that VDR, the main effector of vitamin D's genomic actions, is involved in the regulation of DNA repair factors such as 53BP1 and BRCA1, which have critical roles in the maintenance of genomic stability. During OIS, the expression of Ras activates CTSL-mediated degradation of 53BP1, and the concomitant decrease in VDR expression could contribute to BRCA1 loss.
Next, we tested whether vitamin D supplementation started concomitant with oncogenic Ras expression would have an impact on the onset of senescence (Figures 7c-e ). As shown in Figure 7c , Ras-expressing cells show decreased levels of VDR, which are rescued by 1,25D treatment. We found modest decreases in the percentage of G2-arrested cells (Figure 7d ) and of SA-β-Gal-positive cells (Figure 7e ) at all times tested, however, vitamin D treatment was not sufficient to prevent OIS. Thus, we speculate that although activation of vitamin D/VDR signaling does not impact the onset of OIS, it might improve DNA repair capabilities in senescent cells, reducing the occurrence of secondary hits in the genome that promote malignant transformation.
Vitamin D treatment improves DNA repair in Ras-induced senescent cells Given the reduced BRCA1 and 53BP1 levels observed in Ras-induced senescent cells, we investigated the ability of these factors to be recruited to sites of DNA damage induced by IR. Senescent cells were irradiated, and the formation of DNA repair foci labeled with γH2AX, BRCA1 or 53BP1 was monitored by immunofluorescence. As expected, Ras-senescent cells accumulate basal levels of DNA damage (58% γH2AX-positive), when compared with control cells (15% γH2AX-positive) (Figures 8a and  b) . In contrast, Ras-senescent cells are hindered in their ability to recruit 53BP1 to sites of basal DNA damage (6% 53BP1-positive). This is consistent with the global reduction in 53BP1 levels, which could hinder DNA repair by NHEJ. Importantly, whereas 100% of Ras-senescent cells are positive for γH2AX IRIF formation, and thus able to activate DDR, only 67% show positivity for 53BP1 IRIF, supporting the idea that these cells exhibit DNA repair deficiencies. Significantly, vitamin D treatment of Ras-senescent cells increases 53BP1 foci formation both under basal conditions and in response to IR. Similarly, we found a low percentage of BRCA1-positive cells in irradiated Ras-senescent cells, indicating defects in BRCA1 recruitment to sites of DNA damage, which is indicative of HR defects. Importantly, vitamin D treatment rescues the ability of Ras-senescent cells to recruit BRCA1 to IRIF (Figures 8a and b) .
These results suggest that vitamin D, by stabilizing 53BP1 and BRCA1 levels, restores the function of these important DNA repair factors during Ras-induced senescence. To the best of our knowledge, this is the first report showing the downregulation of DNA repair factors during OIS, and a mechanism through which the DNA repair deficiencies might be, at least in part, rescued.
DISCUSSION
Our study reveals new molecular mechanisms contributing to OIS (Figure 9 ). In particular, expression of oncogenic Ras results in downregulation of VDR and DNA repair factors such as BRCA1 and 53BP1, which are essential for the maintenance of genome stability. Consequently, recruitment of these factors to DNA damage sites is impaired in Ras-induced senescent cells. These alterations are not observed in other types of senescence such as that induced by bleomycin or hydrogen peroxide treatments, indicating that they are not solely the result of growth arrest. Importantly, we uncover an unprecedented role for the vitamin D/VDR axis regulating DNA repair factors during OIS. We find that vitamin D treatment stabilizes VDR, BRCA1 and 53BP1 levels, rescuing at least partially the recruitment of these DNA repair factors to sites of damage in senescent cells. Altogether these studies suggest that Ras-induced senescent cells could be hindered in their ability to deal with endogenous and exogenous DNA-damaging insults, which could facilitate the acquisition of secondary hits in the genome that allow senescence bypass and cellular transformation. Maintaining the levels of VDR in senescent cells could potentially improve their DNA repair capabilities and ameliorate the genomic instability that drives malignancy.
Mechanistically, we propose that reduced expression of VDR during OIS contributes to the downregulation of BRCA1, because depletion of VDR results in decreased BRCA1 transcripts and protein levels, defects in BRCA1 recruitment of DNA damage sites and deficiency in DNA repair by HR. Ligand binding to VDR increases VDR expression, as previously reported in other contexts. 41 This counteracts VDR deficiency during OIS, which in turn increases BRCA1 expression. However, it is likely that activation of vitamin D/VDR signaling impacts other cellular pathways, with consequences for proliferation, senescence and potentially for transformation. Future studies are needed to understand in depth the consequences of VDR deficiency in genomic instability during tumorigenesis.
Importantly, we show for the first time that VDR depletion leads to a prompt growth arrest with characteristics of senescence, which is dependent upon the presence of 53BP1. As such, depletion of 53BP1 abrogates growth arrest in VDR-depleted cells. These results support our previous findings that MCF7 cells depleted of BRCA1 undergo growth arrest owing to the aberrant upregulation of 53BP1-mediated NHEJ, which causes chromosomal instability. 24 In this context, depletion of 53BP1 also prevents the proliferation arrest. Our findings are also consistent with landmark studies showing that 53BP1 loss is synthetically viable with the loss of BRCA1, and that the imbalance between 53BP1 and BRCA1 causes genomic instability and growth arrest. [16] [17] [18] 22, 23 Our data suggest that 53BP1 has a major role in the growth arrest imposed by VDR loss and HR deficiency, acting as a tumor suppressor mechanism. Consistent with this notion, reduced expression of 53BP1 has been observed in breast tumors from patients carrying germ-line mutations in BRCA1, and in TNBC, which are often deficient in DNA repair by HR. 16, 24 On the basis of all these data, we propose that 53BP1 has an active role in senescence induced by genomic instability due to HR defects, such as in BRCA1-and VDR-depleted cells, and that loss of 53BP1 allows evasion of this barrier to tumor progression. Importantly, the fact that Ras-induced senescent cells reduce 53BP1 levels during the senescence phase in the context of BRCA1 deficiency support the idea that these cells could be more prone to transformation, when compared with other senescent cells where BRCA1 and 53BP1 remain highly expressed. In tissues, OIS is thought to arrest tumor growth before cells become malignant. 42 Thus, senescent cells are typically observed in benign neoplastic lesions, but not in malignant cancers. Interestingly, analysis of several benign and malignant human neoplasms revealed a clear (2)). Representative images of SA-β-Gal staining are shown. (e) Cell cycle analysis shows accumulation of cells in G1 phase of the cell cycle after VDR depletion (n = 3 for shVDR(1) and n = 2 for shVDR(2)).
abundance of 53BP1-labeled DNA repair foci in benign lesions, and a marked decrease in 53BP1 positivity in cancerous lesions, including melanomas and invasive breast and colon carcinomas. 43 The role of 53BP1 in tumor suppression stresses the importance of identifying molecular mechanisms responsible for its loss in tumor cells and in senescent cells, as shown in this study. These mechanisms could represent novel therapeutic targets. Our previous studies identified one molecular mechanism regulating 53BP1 levels. We found that upregulation of CTSL and its entry into the nucleus is responsible for 53BP1 protein degradation in a variety of contexts, that is, mouse embryonic fibroblasts deficient in lamin A/C, 26 MCF7 cells depleted of BRCA1, 24 and primary human fibroblasts and MCF7 cells growth arrested by contact inhibition or serum deprivation. 25 As such, depletion of CTSL in all these contexts results in the stabilization of 53BP1, rescuing its targeting to DNA repair sites. Here, we show that this mechanism of regulation of 53BP1 is also activated during Ras-induced senescence. This finding is highly significant, Figure 6 . 53BP1 depletion rescues growth arrest in VDR-depleted cells. (a) MCF7 cells carrying an HR reporter construct (DR-GFP) were lentivirally transduced with shRNA targeting VDR or shRNA control (shscr). We monitored the percentage of GFP-positive cells resulting from HR of I-SceI-induced DSBs by fluorescence-activated cell sorting in four independent experiments. Note how depletion of VDR (immunoblotting) results in decreased HR efficiency. (b) BJ+hTert fibroblasts were depleted of 53BP1 via lentiviral transduction with specific shRNA (sh53BP1) prior to depletion of VDR (shVDR). Hairpins shscr and shLuc were used as control for the depletions. After dual selection, cells were processed for immunoblotting to monitor the levels of BRCA1, VDR and 53BP1. Vinculin was used as loading control. (c) Percentage of cells positive for SA-β-Gal activity was calculated 6 days after the second lentiviral transduction with shRNAs. Graph shows average ± s.e.m. of two biological repeats. (d) Proliferation of the different cell lines generated was evaluated by counting cells days 2-11 after dual selection, as described in methods. The graph shows average ± s.e.m. of four biological repeats. Note how depletion of 53BP1 prevents growth arrest in VDR-depleted cells (day 11, *P = 0.001). because upregulation of CTSL has been observed in a variety of cancers and associated with increased invasiveness, metastasis and overall degree of malignancy. [44] [45] [46] Future studies need to determine whether activation of CTSL-mediated degradation of 53BP1 in senescent cells contributes to senescence bypass and transformation. Importantly, we demonstrate the ability to regulate 53BP1 protein levels by vitamin D treatment in senescent cells. Our study reveals a new potential therapeutic strategy to maintain 53BP1 levels in senescent cells as well as in cells already transformed. In particular, maintaining high levels of 53BP1 could prevent proliferation and survival of senescent or transformed cells that exhibit genomic instability due to defects in HR. The importance of the vitamin D/VDR axis in tumor suppression has been extensively reported. Epidemiological studies showed that vitamin D/VDR deficiency enhances cancer risk, and that vitamin D treatment has anti-proliferative effects in a variety of cancers. 47, 48 In addition, VDR expression has been associated with improved overall survival in cancer patients, including patients with tumors of poor prognosis such as human glioblastoma multiforme 49 and non-small cell lung cancer. 50 Moreover, a high prevalence of vitamin D deficiency has been reported among African-American women, who are disproportionately affected by TNBC. [51] [52] [53] The TNBC phenotype is associated with mutations in BRCA1 and defects in HR, thus suggesting that VDR deficiency could be linked to the high incidence of these tumors in African-American women. However, the molecular mechanisms by which deficiencies in the vitamin D/VDR axis contribute to malignancy remain poorly understood. This study and our previous findings 24,26,54 support a role for vitamin D/VDR regulating DNA repair factors with key roles in the maintenance of genome stability. Here, we demonstrate that VDR depletion results in BRCA1 reduction and HR defects, which in turn results in a prompt growth arrest of primary human cells. Activation of CTSL-mediated degradation of 53BP1 in senescent cells, either due to direct upregulation of CTSL, such as in Ras-induced senescent cells, or via alternative unknown mechanisms, could prime cells for senescence bypass. In the context of tumor cells, VDR and BRCA1 deficiencies would in principle sensitize tumor cells to DNA-damaging strategies. However, we also found a correlation between VDR deficiency and loss of 53BP1, 24 a well-known mechanism of therapy resistance, in BRCA1-related tumors and TNBCs. [55] [56] [57] [58] [59] Thus, we hypothesize that vitamin D/VDR deficiency promotes malignancy by causing DNA repair defects, while allowing the activation of mechanisms of therapy resistance. Future studies need to determine whether vitamin D treatment could represent a new strategy to stabilize 53BP1 in the context of BRCA1 deficiency, restoring the sensitivity of specific tumor cells to DNA-damaging strategies currently used in the clinic for cancer treatment.
MATERIALS AND METHODS

Cell culture
Human foreskin (BJs) and lung (IMR90) fibroblasts expressing telomerase (hTERT) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum+1% antibiotics/antimycotics. Bleomycin treatment. Bleomycin was used to induce senescence of fibroblasts (BJ+hTert). Cells were incubated with 100 μg/ml bleomycin for 24 h in complete medium. Bleomycin was then removed by extensive washing with phosphate-buffered saline, and cells were grown for 72 h in complete medium and collected for different assays.
Hydrogen peroxide treatment. Hydrogen peroxide was used to induce senescence of fibroblasts (BJ+hTert). Cells were incubated with 500 μM hydrogen peroxide for 1 h in complete medium, washed extensively in phosphate-buffered saline and cultured in complete medium for 4 days. Cells were then treated with 200 μM hydrogen peroxide for 2 h, washed with phosphate-buffered saline and cultured for additional 4-6 days. After 2 weeks from the first treatment, cells were collected and processed for different assays.
Hydroxyurea treatment. Cells were grown in complete medium supplemented with 600 μM hydroxyurea (or vehicle), freshly replaced every 2 days. After 2 weeks from the first treatment, cells were collected and processed for different assays. (a) Expression of oncogenic Ras in human primary fibroblasts results in upregulation of the cysteine protease CTSL, which in turn is responsible for the degradation of 53BP1 protein during OIS. In addition, oncogenic Ras expression leads to downregulation of VDR, which in turn contributes to a reduction in BRCA1 expression. VDR deficiency and loss of DNA repair factors during OIS could contribute to the genomic instability that drives senescence bypass and cellular transformation over time. (b) Vitamin D (1,25D) treatment increases VDR expression, as previously reported in other contexts. 41 Increased vitamin D/VDR signaling results in upregulation of BRCA1 expression and inhibition of CTSL-mediated degradation of 53BP1, as reported. 26 As a consequence, vitamin D treatment rescues DNA repair defects in senescent cells. Maintaining vitamin D/VDR levels could ameliorate the occurrence of secondary hits in the genome that promote senescence bypass and malignant transformation. cells at day 4 post infection were treated with 1,25D for 48 or 72 h, replacing fresh 1,25D-containing medium daily. Prolonged treatment: 1,25D was administrated to cells concomitantly with the expression of oncogenic Ras, replacing fresh 1,25D-containing medium every 2 days.
Ionizing radiation. For assessing the ability of Ras-senescent cells to form DNA repair foci, cells were irradiated with 3 Gy and fixed and processed for immunofluorescence 3 or 6 h post irradiation to monitor 53BP1 and BRCA1 IRIF foci formation, respectively. As control for DNA damage, γH2AX IRIF were monitored at both time points as well. For the time course experiment of DNA repair foci formation/dissolution, cells were irradiated with 1 Gy and fixed at different time points (1-24 h) post irradiation.
Constructs and viral transduction
Retroviral and lentiviral transductions were performed as previously described. 60 Details are provided in Supplementary Information.
Senescence markers
To monitor senescence, we performed analyses of cell cycle profile, positivity for SA-β-Gal activity, presence of senescence-associated heterochromatic foci and expression of cyclin A and p21. Assays are described in detail in Supplementary Information.
Proliferation assay
To monitor the rate of proliferation, cells were plated in triplicate at 500 000 cells/10-cm plate and counted every 2 days utilizing Trypan Blue Viability Assay on the Nexcelom Cellometer Vision CBL (Nexcelom Bioscience, Lawrence, MA, USA). To extrapolate proliferation to the respective time periods, we used the equation N f = N o e kt , where N f is the final number of cells, N o is the starting number of cells, k is ln2/DT (doubling time) and t is time in days. For each period, we calculated the doubling time and used it to estimate the number of cells (N f ) that would result from initially plating 500 000 (N 0 ) and culturing them for a given period of time.
Immunoblotting, immunofluorescence and qRT-PCR These were performed using standard protocols described before. 24, 25, 28 Details are provided in Supplementary Information. HR assays HR was measured in MCF7-pDR-GFP cells by flow cytometry as described. 61 Microscopy Microscopy and photo capture was performed on a Leica (Leica Microsystems Inc., Buffalo Grove, IL, USA) DM5000 B microscope using × 40 or × 63 oil objective lenses with a Leica (Leica Microsystems Inc.) DFC350FX digital camera and the Leica Application Suite (Version 4.1.0).
Statistical analysis
A standard 'two-tailed' student's t-test was used to calculate statistical significance of the observed differences between two independent samples. When comparisons were made among more than two samples, we used one-way analysis of variance. All graphs show average ± s.e.m. of at least three biological repeats. GraphPad Prism 6 was used for the calculations. Differences were considered statistically significant when Po0.05.
